3 completed, 1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Carcinoma, Thymic: new trials by email Literature Review of Carcinoma, Thymic trials Research Report on Carcinoma, Thymic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers KFA115, pembrolizumab - Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2022-10-26 | 2026-10-20 |
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Atezolizumab - Carcinoma, Thymic | Phase 2 | Completed | Hoffmann-La Roche | 34 | 2020-08-07 | 2024-06-11 |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies AZD6244, MK-2206, Lapatinib - Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Completed | National Cancer Institute (NCI) | 647 | 2011-02-08 | 2024-10-01 |
Thymoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Anus Neoplasms (3) · Carcinoma, Renal Cell (3) · Esophageal Neoplasms (3) · Lung Neoplasms (3) · Mesothelioma (3) · Ovarian Neoplasms (3) · Appendiceal Neoplasms (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Cholangiocarcinoma (2) · Colonic Neoplasms (2)
Hemic and Lymphatic Diseases (5) · Lymphatic Diseases (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Complex and Mixed (5) · Thoracic Neoplasms (5) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Lung Diseases (4) · Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thymus Neoplasms (4) · Adenocarcinoma (3) · Adenoma (3)
AZD 6244 (1) · Erlotinib Hydrochloride (1) · Lapatinib (1) · MK 2206 (1) · Sunitinib (1) · atezolizumab (1) · pembrolizumab (1)
Travera Inc (2) · Hoffmann-La Roche (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1)
United States (3) · China (2) · Canada (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
Arun Rajan, M.D. (1) · Mark Stevens, Ph.D. (1) · Mark Stevens, Phd (1) · Rob Kimmerling, Phd (1) · Robert Kimmerling, Ph.D. (1)